IPP Bureau
Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
By IPP Bureau - October 09, 2023
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
American Oncology Institute launched Bone Marrow Transplant programs in India
By IPP Bureau - October 09, 2023
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Dozee unveils ‘Dozee Pro Ex’ for seamless continuum of monitoring from hospital to home
By IPP Bureau - October 09, 2023
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
Veramed acquires Clinical Trial Data Services
By IPP Bureau - October 09, 2023
Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.
Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments
By IPP Bureau - October 09, 2023
Increased capability to produce medicines for challenging diseases including cancer
Biocon Biologics gets complete response letter from USFDA for Biosimilar Insulin Aspart
By IPP Bureau - October 09, 2023
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada
By IPP Bureau - October 09, 2023
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Zydus receives final approval from the USFDA for Sugammadex Single-Dose Vial
By IPP Bureau - October 09, 2023
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
India has taken a lead in Preventive and Integrated Healthcare, says Dr Jitendra Singh
By IPP Bureau - October 09, 2023
Dr. Singh proposes upskilling medicos with AI, Quantum and other newer technologies to meet the changing requirements of patient care
Mitsui invests in Lokavant Holdings
By IPP Bureau - October 09, 2023
Lokavant provides clinical trial intelligence
Reclassify nicotine replacement therapies as prescription drugs, says Doctor
By IPP Bureau - October 07, 2023
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
By IPP Bureau - October 07, 2023
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Emmes acquires VaxTRIALS
By IPP Bureau - October 07, 2023
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Cambrex completes US$38 million capacity expansion in High Point, North Carolina
By IPP Bureau - October 07, 2023
